Investor Relations

A leadership story in the field of advanced cell therapy

Investor Relations

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aastrom Biosciences Corrects Warrant Exercise Price Related to April 5, 2004 Sale of Common Stock
Aastrom Biosciences Corrects Warrant Exercise Price Related to April 5, 2004 Sale of Common Stock Ann Arbor, Michigan, April 6, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that the exercise price of the warrants issued to a group of institutional investors was $1.65 per share
View HTML
Toggle Summary Aastrom Biosciences Announces $9.1 Million Private Placement of Common Stock
Aastrom Biosciences Announces $9.1 Million Private Placement of Common Stock Ann Arbor, Michigan, April 5, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it has placed 8 million shares of common stock with institutional investors at approximately $1.14 per share, for an
View HTML
Toggle Summary Aastrom Biosciences Announces the Initiation of a Clinical Trial for Bone Grafting in Spain
-- Aastrom's Proprietary TRCs to be Utilized in Second European Clinical Study to Treat Major Bone Fractures --
View HTML
Toggle Summary Aastrom Biosciences Further Facilitates Process for Participation in Direct Stock Purchase Program
-- New Form Simplifies Enrollment for Shareholders with Shares in "Street Name" --
View HTML
Toggle Summary Aastrom Biosciences Receives Patent for Transplantation Use of Its Stem Cell Products
-- Patent Covers Bone Marrow, Blood and Cord Blood-Sourced Products --
View HTML
Toggle Summary Aastrom Biosciences' CEO to Present at Roth Capital Partners 16th Annual Growth Stock Conference
Aastrom Biosciences' CEO to Present at Roth Capital Partners 16th Annual Growth Stock Conference Ann Arbor, Michigan, February 12, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that R. Douglas Armstrong, Ph.D., Chairman, President and Chief Executive Officer, has been invited
View HTML
Toggle Summary Linda Manoogian Fingerle Appointed to Aastrom Biosciences' Board of Directors
Linda Manoogian Fingerle Appointed to Aastrom Biosciences' Board of Directors Ann Arbor, Michigan, February 5, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that Linda Manoogian Fingerle was appointed to the Company's Board of Directors. Ms.
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports Second Quarter Fiscal Year 2004 Financial Results
Aastrom Biosciences, Inc. Reports Second Quarter Fiscal Year 2004 Financial Results Ann Arbor, Michigan, February 4, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM), today reported financial results for the second quarter of fiscal year 2004 ended December 31, 2003.
View HTML
Toggle Summary astrom Biosciences to Hold Investor Conference Call Tomorrow
astrom Biosciences to Hold Investor Conference Call Tomorrow Ann Arbor, Michigan, February 3, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will hold an investor conference call tomorrow, Wednesday, February 4, 2004 at 11:00 a.m. EST.
View HTML
Toggle Summary Aastrom Biosciences to Hold Investor Conference Call
Aastrom Biosciences to Hold Investor Conference Call Ann Arbor, Michigan, January 30, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it will hold an investor conference call on Wednesday, February 4, 2004 at 11:00 a.m. EST. The call is intended to bring shareholders and
View HTML

Day High:
Day Low:
Volume:
on
Copyright West LLC. Minimum 15 minutes delayed.